ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022 ZORYVE is a once-daily non-steroidal cream and the first and ...
Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5 All three of the largest pharmacy benefit managers in the United States have now included ...
Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...
Zoryve cream 0.05% is available in a 60g tube. Zoryve ® (roflumilast) cream 0.05% is now available for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...
Zoryve (roflumilast) cream 0.15 percent can help improve itch, the most bothersome atopic dermatitis symptom, in as soon as 24 hours. Side effects were minimal and mild in clinical trials. Because ...
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation ...
Individual patient response data highlights 95% of individuals treated with ZORYVE had a measurable improvement in Psoriasis Area and Severity Index (PASI) at Week 8 Over 85% achieved measurable ...
WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback